318 related articles for article (PubMed ID: 21365219)
1. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
[TBL] [Abstract][Full Text] [Related]
2. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
6. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
Fleming MT; Sonpavde G; Kolodziej M; Awasthi S; Hutson TE; Martincic D; Rastogi A; Rousey SR; Weinstein RE; Galsky MD; Berry WR; Wang Y; Boehm KA; Asmar L; Rauch MA; Beer TM
Clin Genitourin Cancer; 2012 Mar; 10(1):6-14. PubMed ID: 22340631
[TBL] [Abstract][Full Text] [Related]
7. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
Sridhar SS; Canil CM; Chi KN; Hotte SJ; Ernst S; Wang L; Chen EX; Juhasz A; Yen Y; Murray P; Zwiebel JA; Moore MJ
Cancer Chemother Pharmacol; 2011 Apr; 67(4):927-33. PubMed ID: 20602233
[TBL] [Abstract][Full Text] [Related]
9. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
11. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P
Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
[TBL] [Abstract][Full Text] [Related]
12. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
[TBL] [Abstract][Full Text] [Related]
13. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
15. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.
Di Lorenzo G; Buonerba C; Faiella A; Rescigno P; Rizzo M; Autorino R; Perdonà S; Riccardi N; Scagliorini S; Scognamiglio F; Masala D; Ferro M; Palmieri G; Aieta M; Marinelli A; Altieri V; De Placido S; Cartenì G
BJU Int; 2011 Jan; 107(2):234-9. PubMed ID: 20590545
[TBL] [Abstract][Full Text] [Related]
17. Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.
Polyzos A; Tsavaris N; Kosmas C; Polyzos K; Giannopoulos A; Felekouras E; Nikiteas N; Kouraklis G; Griniatsos J; Safioleas M; Stamatakos M; Pikoulis E; Papachristodoulou A; Gogas H
Anticancer Res; 2006; 26(5B):3749-53. PubMed ID: 17094396
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
19. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
Takaha N; Okihara K; Kamoi K; Hongo F; Iwata T; Yano K; Ueda T; Takeuchi I; Yamada T; Kawauchi A; Miki T
Urol Int; 2011; 87(3):263-9. PubMed ID: 21876321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
